A prospective study on the incidence of rheumatoid arthritis among people with persistent increase of rheumatoid factor

H D Halldórsdóttir, T Jónsson, J Thorsteinsson, H Valdimarsson

Abstract

Objectives—To study the stability of rheumatoid factor (RF) increases and to compare the incidence of rheumatoid arthritis (RA) in people with transient or persistent increase of one or more RF isotypes.

Methods—From an original cohort of nearly 14 000 participants in a population study, 135 previously RF positive persons were recruited in 1996 and evaluated according to the 1987 ACR criteria. The observation time ranged from 9–22 years (mean 16.5). Blood samples were obtained from all participants at entry and again in 1996.

Results—About 40% of the participants who had only one raised RF isotype in the original sample had become RF negative in 1996 compared with only 15% of those with increase of two or three RF isotypes (p=0.002). The seven participants who developed RA during the study period all had persistently raised RF. Six of the 54 participants with more than one RF isotype raised in 1996 developed RA, corresponding to an annual incidence of 0.67%, which was 7.5 times higher than observed in the other participants (p=0.045).

Conclusion—Symptom free persons with persistently raised RF have greatly increased risk of developing RA. This suggests that dysregulation of RF production is a predisposing factor in RA.


Rheumatoid factor (RF) may play an important part in normal immune responses and increased RF is occasionally found in apparently healthy people. Increased concentration of RF is found in most rheumatoid arthritis (RA) patients although it can also be increased in other rheumatic diseases and in infections. However, a combined increase of IgA and IgM RF is almost exclusively found in RA and has therefore a high diagnostic specificity for this disease. Population surveys have shown that the majority of people with increased RF do not have symptoms of rheumatic diseases or chronic infections. The role of RF in the pathogenesis of RA is therefore not clear, and reports are lacking on the stability of increased RF isotypes and the risk of symptom free people with persistently raised RF to develop RA. However, increase of RF has been found to precede clinical symptoms of RA and the pre-rheumatoid RF isotype patterns have been similar to those observed in established disease.

Aho et al have estimated that the prevalence of seropositive arthritis in Finland is approximately 0.5% in men and 1.1% in women, increasing progressively from the age of 30 to 69 years, whereafter it seemed to level off. Reports from other countries have shown an overall prevalence of approximately 1%. The annual incidence of RA in adult white populations has been reported to lie between 0.022 and 0.06% in different studies. We have previously reported that symptom free people with raised RF have increased risk of developing RA compared with matched RF negative controls. This paper reports a serological and clinical follow up on the previously seropositive participants of this study with an average observation time of 16.5 years.

Methods

STUDY BACKGROUND

A prospective health survey has been conducted in the Reykjavik area by The Icelandic Heart Association since November 1967. Collection of data relating to rheumatic diseases and RF started in 1968 and the original study design has been described. Briefly, the participants were born between 1907 and 1935 and selected randomly from all inhabitants in the Reykjavik area of Iceland. Between 1974 and 1983 a total of 16 299 blood samples were collected from 13 858 participants who were all evaluated for symptoms of rheumatic diseases. These blood samples were tested for RF by the Rheumaton agglutination slide test, and positive samples were tested further by the Rose-Waaler (RW) technique. All samples with a RW titre of 1/10 or more were measured for IgM, IgG and IgA RF isotypes by ELISA. The participants were considered seropositive if they had two or more RF isotypes above the 95% cut off as determined by 200 randomly selected age matched controls. Participants with two RF isotypes under the 95% cut off level were only included if their third RF isotype was above the 97.5% cut off level.

In 1987 all available RF positive participants (n=173) and age and sex matched RF negative participants (n=156) were evaluated clinically and new blood samples collected. None of the 156 RF negative controls from the 1987 study were included in this study.

SELECTION OF PARTICIPANTS FOR EVALUATION IN 1996

In addition to the 173 RF positive participants in the 1987 study, 46 people who had been RF

Departments of Immunology and Rheumatology, National University Hospital, Reykjavik, Iceland

Correspondence to: Professor H Valdimarsson, Department of Immunology, National University Hospital Landspítali, 101 Reykjavik, Iceland

Accepted for publication 21 October 1999
positive in the original blood sample but could not be recruited to the study in 1987 were considered eligible for this study. Of these 219 persons 52 had died in 1996. Of the 167 that were thus potentially available 135 (81%) could be recruited to this study, including 115 of the 173 seropositive participants from 1987 and 20 people who had previously been RF positive by agglutination and ELISA but were unable to participate in the 1987 study. The remaining 32 had either moved from the Reykjavik area or could not be traced. The participants, 62 men and 73 women, were all evaluated by structured interview and physical examination according to the American College of Rheumatism (ACR) criteria from 1987 without knowledge of previous clinical or RF findings, and new blood samples were collected. Thus, at least two blood samples from each participant, taken at an interval of 9–22 years (mean 16.5) were tested for RF isotypes. It should be noted that before 1987 RF had been measured only by agglutination in a few of the participants. Thus, their isotypes were first measured in 1987. As the incidence of RA was evaluated in the context of RA isotypes in this study, an observation time of only nine years could be taken into account for these people.

Table 1  Stability of increased RF isotypes and prevalence of RA during the follow up period

<table>
<thead>
<tr>
<th>Increased RF isotypes in 1996 (number of RA patients)</th>
<th>None</th>
<th>One</th>
<th>Two or three</th>
</tr>
</thead>
<tbody>
<tr>
<td>One RF isotype (n=64)</td>
<td>26 (38%)</td>
<td>21 (31%)</td>
<td>21 (31%)</td>
</tr>
<tr>
<td>Two or three RF isotypes (n=67)</td>
<td>10 (15%)</td>
<td>10 (16%)</td>
<td>47 (70%)</td>
</tr>
<tr>
<td>Total (n=135)†</td>
<td>36 (27%)</td>
<td>31 (23%)</td>
<td>68 (50%)</td>
</tr>
</tbody>
</table>

*Numbers in parentheses show the 22 RA patients in relation to past and present RF findings. †All numbers in parentheses show the 135 people who had previously been RF positive by agglutination and ELISA but were unable to participate in the 1987 study. The observation period, which ranged from 9 to 22 years (mean 16.5), was tested for RF isotypes. It should be noted that before 1987 RF had been measured only by agglutination in a few of the participants. Thus, their isotypes were first measured in 1987. As the incidence of RA was evaluated in the context of RA isotypes in this study, an observation time of only nine years could be taken into account for these people.

Table 2  Incidence of RA and RF findings in blood samples from 1974–1987

<table>
<thead>
<tr>
<th>Development of RA during the study period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased RF isotypes in original blood samples</td>
</tr>
<tr>
<td>One RF isotype (n=64)</td>
</tr>
<tr>
<td>Two or three RF isotypes (n=56)</td>
</tr>
<tr>
<td>Total (n=120)</td>
</tr>
</tbody>
</table>

*One of these two patients had both IgM and IgA RF raised in his 1996 sample. †Four of these patients had combined increase of IgM and IgA RF.

Table 3  Incidence of RA and RF findings in blood samples from 1996

<table>
<thead>
<tr>
<th>Development of RA during the study period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased RF isotypes in 1996 blood sample</td>
</tr>
<tr>
<td>Group 1: No RF isotype (n=36)</td>
</tr>
<tr>
<td>Group 2: One RF isotype (n=30)</td>
</tr>
<tr>
<td>Group 3: Two or three RF isotypes (n=54)</td>
</tr>
</tbody>
</table>

Group 1 versus groups 2 and 3: p=0.074. Groups 1 and 2 versus group 3: p=0.045. *Isolated IgM RF. †Five of these patients had two or three isotypes increased in the original blood sample. ‡The approximate annual RA incidence and 95% confidence intervals in Finnish adults (≥16 years) was 0.029 (0.025, 0.032).*
suggesting that they might have developed a transient RA that had subsided when this study was carried out.

**Discussion**

In this study the long term stability of RF isotype increases was evaluated in the context of prevalence of RA and the risk of developing this disease. In agreement with previous studies, increase of RF was very stable (100%) in the RA patients, but it was also relatively stable in participants who had still not developed RA, especially in those with a combined increase of IgM and IgA RF (74%).

The prevalence of RA has been estimated to be approximately 1% among white populations but it was 16% in our RF positive study cohort. It is of interest that participants with increased concentrations of both IgM and IgA RF in 1996 had about 10 times higher prevalence of RA than those who had become seronegative or had only one persistently increased RF isotype (table 1). This agrees with the finding that IgM and IgA RF is characteristic for RA patients. Eberhardt et al have reported similar RF isotype increases in early RA and divergent findings may in part be attributable to methodological differences.

Increase of RF before clinical onset of RA is well documented. The annual incidence rate of RA has in several studies been reported to be 0.022% to 0.06%, and in Finland the annual incidence of seropositive RA was estimated to be about 0.03% between 1980 and 1990. We have previously reported that about 5% of 173 symptom free subjects with increased RF developed RA during a mean observation time of 9.6 years compared with none of 156 age and sex matched RF negative controls. Our present findings indicate that people with an increase of more than one RF isotype have an annual RA incidence of 0.67%, which is about 22 times higher than was observed for RF positive RA in the adult Finish population between 1980 and 1990. Furthermore, epidemiological studies have shown an annual incidence rates ranging from 0.074 to 0.157 for people over 40 years. However, the mean age at diagnosis of RA increased from 50.2 to 57.8 years between 1975 and 1990. It is not known whether this also applies to Iceland.

In conclusion, our findings show that an increase of RF is relatively stable even in symptom free persons, especially when more than one RF isotype is raised. Furthermore, symptom free people with stable increase of RF have a markedly increased incidence of RA, the predominant RF pattern being a combined increase in IgM and IgA RF. The fact that increases of RF can precede clinical disease for a long period of time indicates that factors regulating RF production may play a primary part in the pathogenesis of RA.

We thank Drs Amsundur Brekkan and Níkulas Sigfússon for their contribution to this study.

Funding: this study was funded by The Icelandic Science Foundation and the National Hospital Science Fund.

A prospective study on the incidence of rheumatoid arthritis among people with persistent increase of rheumatoid factor

H D Halldórsdóttir, T Jónsson, J Thorsteinsson and H Valdimarsson

Ann Rheum Dis 2000 59: 149-151
doi: 10.1136/ard.59.2.149

Updated information and services can be found at: http://ard.bmj.com/content/59/2/149

These include:

References
This article cites 14 articles, 4 of which you can access for free at: http://ard.bmj.com/content/59/2/149#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Connective tissue disease (4253)
Degenerative joint disease (4641)
Immunology (including allergy) (5144)
Musculoskeletal syndromes (4951)
Rheumatoid arthritis (3258)

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/